PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.

Covid19 Vaccine Clinical Trial

Official title:
A Phase 2, Randomized, Double-dummy, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Compared to Pfizer-BioNTech COVID-19 Vaccine in Healthy Seronegative Adults Aged 18 to 64 Years

Status Completed

Clinical Trial Summary

The Vaccine Product, PTX-COVID19-B mRNA Humoral Vaccine, is intended for prevention of COVID-19 in a general population. This study is designed to evaluate the safety, tolerability, and immunogenicity of PTX-COVID19-B compared to Pfizer-BioNTech COVID-19 vaccine in healthy seronegative adults aged 18 to 64.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05175742
Study type	Interventional
Source	Providence Therapeutics Holdings Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	August 17, 2021
Completion date	March 29, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05079633` - A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults	Phase 4
Completed	`NCT05011526` - A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults	Phase 3
Completed	`NCT04822025` - A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults	Phase 2
Completed	`NCT04818892` - Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease
Completed	`NCT04951388` - A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents	Phase 2
Not yet recruiting	`NCT04730895` - Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.	Phase 1/Phase 2
Completed	`NCT05048849` - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study	Phase 2
Completed	`NCT04765436` - PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64	Phase 1
Active, not recruiting	`NCT04760704` - Covid-19 Vaccine Response in Elderly Subjects
Completed	`NCT04695652` - A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult	Phase 2
Withdrawn	`NCT05029245` - IntraDermal Versus Intramuscular Comirnaty® Efficacy Study	Phase 3
Completed	`NCT05038618` - A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study	Phase 2
Recruiting	`NCT04834869` - COVID-19 Vaccines Safety Tracking (CoVaST)